Abstract
Mice deficient in the adaptor Src homology 2 domain-containing leukocyte phosphoprotein of 76 kD (SLP-76) exhibit a bleeding disorder and lack T cells. Linker for activation of T cells (LAT)-deficient mice exhibit a similar T cell phenotype, but show no signs of hemorrhage. Both SLP-76 and LAT are important for optimal platelet activation downstream of the collagen receptor, GPVI. In addition, SLP-76 is involved in signaling mediated by integrin αIIbβ3. Because SLP-76 and LAT function coordinately in T cell signal transduction, yet their roles appear to differ in hemostasis, we investigated in detail the functional consequences of SLP-76 and LAT deficiencies in platelets. Previously we have shown that LAT−/− platelets exhibit defective responses to the GPVI-specific agonist, collagen-related peptide (CRP). Consistent with this, we find that surface expression of P-selectin in response to high concentrations of GPVI ligands is reduced in both LAT- and SLP-76–deficient platelets. However, platelets from LAT−/− mice, but not SLP-76−/− mice, aggregate normally in response to high concentrations of collagen and convulxin. Additionally, unlike SLP-76, LAT is not tyrosine phosphorylated after fibrinogen binding to integrin αIIbβ3, and collagen-stimulated platelets deficient in LAT spread normally on fibrinogen-coated surfaces. Together, these findings indicate that while LAT and SLP-76 are equally required for signaling via the T cell antigen receptor (TCR) and pre-TCR, platelet activation downstream of GPVI and αIIbβ3 shows a much greater dependency on SLP-76 than LAT.
Bibliography
Judd, B. A., Myung, P. S., Obergfell, A., Myers, E. E., Cheng, A. M., Watson, S. P., Pear, W. S., Allman, D., Shattil, S. J., & Koretzky, G. A. (2002). Differential Requirement for LAT and SLP-76 in GPVI versus T Cell Receptor Signaling. The Journal of Experimental Medicine, 195(6), 705â717.
References
53
Referenced
70
10.1016/S0952-7915(00)00085-6
/ Curr. Opin. Immunol. (2000)10.1074/jbc.270.13.7029
/ J. Biol. Chem. (1995)10.1016/S0092-8674(00)80901-0
/ Cell. (1998)10.4049/jimmunol.161.8.3880
/ J. Immunol. (1998)10.1074/jbc.273.51.34437
/ J. Biol. Chem. (1998)10.1074/jbc.271.33.19641
/ J. Biol. Chem. (1996)10.4049/jimmunol.157.9.3769
/ J. Immunol. (1996)10.1016/S1074-7613(00)80485-9
/ Immunity. (1996)10.1084/jem.184.3.1161
/ J. Exp. Med. (1996)10.1074/jbc.271.36.22225
/ J. Biol. Chem. (1996)10.1128/MCB.20.5.1461-1477.2000
/ Mol. Cell. Biol. (2000)10.1016/S1074-7613(00)80658-5
/ Immunity. (1998)10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R
/ Eur. J. Immunol. (1999)10.1074/jbc.275.6.3835
/ J. Biol. Chem. (2000)10.1074/jbc.275.3.2219
/ J. Biol. Chem. (2000)10.1016/S1074-7613(01)00175-3
/ Immunity. (2001)10.1074/jbc.272.18.11674
/ J. Biol. Chem. (1997)10.1073/pnas.94.14.7493
/ Proc. Natl. Acad. Sci. USA. (1997)10.1126/science.1063486
/ Science. (2001)10.1126/science.1063397
/ Science. (2001)10.1083/jcb.149.1.181
/ J. Cell Biol. (2000)10.1074/jbc.M010639200
/ J. Biol. Chem. (2001)10.1016/S0960-9822(99)80017-7
/ Curr. Biol. (1999)10.1084/jem.189.9.1383
/ J. Exp. Med. (1999)10.1084/jem.189.8.1243
/ J. Exp. Med. (1999)10.1016/S1074-7613(00)80606-8
/ Immunity. (1998)10.1084/jem.192.7.1047
/ J. Exp. Med. (2000)10.1016/S1074-7613(00)80577-4
/ Immunity. (1998)10.1042/bj3330373
/ Biochem. J. (1998)10.1074/jbc.M102221200
/ J. Biol. Chem. (2001)10.1084/jem.194.2.135
/ J. Exp. Med. (2001)10.1074/jbc.M001439200
/ J. Biol. Chem. (2000)10.1126/science.281.5375.416
/ Science. (1998)10.1016/S0092-8674(00)81422-1
/ Cell. (1998)10.1172/JCI5317
/ J. Clin. Invest. (1999)10.1074/jbc.274.9.5963
/ J. Biol. Chem. (1999)10.1073/pnas.97.22.12056
/ Proc. Natl. Acad. Sci. USA. (2000)10.1016/S1074-7613(00)80032-1
/ Immunity. (1999)10.1128/MCB.19.12.8326
/ Mol. Cell. Biol. (1999)10.1126/science.1057176
/ Science. (2001)10.1074/jbc.M009344200
/ J. Biol. Chem. (2001)10.1042/bj3060337
/ Biochem. J. (1995)10.1182/blood.V91.11.4206
/ Blood. (1998)10.1084/jem.183.4.1937
/ J. Exp. Med. (1996)10.1182/blood.V92.10.3780
/ Blood. (1998)10.1073/pnas.90.18.8392
/ Proc. Natl. Acad. Sci. USA. (1993)10.1080/09537100050129260
/ Platelets. (2000)10.1093/emboj/16.21.6414
/ EMBO J. (1997)10.1016/S0167-5699(00)01716-3
/ Immunol. Today (2000){'key': '2023072511285666900_BIB50', 'first-page': '1737', 'volume': '103', 'year': '1999', 'journal-title': 'J. Clin. Invest.'}
/ J. Clin. Invest. (1999)10.1016/S1074-7613(00)80204-6
/ Immunity. (2000)10.1038/88756
/ Nat. Immunol. (2001)10.1128/MCB.21.13.4208-4218.2001
/ Mol. Cell. Biol. (2001)
Dates
Type | When |
---|---|
Created | 23 years, 1 month ago (July 26, 2002, 12:48 p.m.) |
Deposited | 2 years, 1 month ago (July 25, 2023, 7:30 a.m.) |
Indexed | 5 months ago (March 30, 2025, 4:44 p.m.) |
Issued | 23 years, 5 months ago (March 18, 2002) |
Published | 23 years, 5 months ago (March 18, 2002) |
Published Online | 23 years, 5 months ago (March 18, 2002) |
Published Print | 23 years, 5 months ago (March 18, 2002) |
@article{Judd_2002, title={Differential Requirement for LAT and SLP-76 in GPVI versus T Cell Receptor Signaling}, volume={195}, ISSN={0022-1007}, url={http://dx.doi.org/10.1084/jem.20011583}, DOI={10.1084/jem.20011583}, number={6}, journal={The Journal of Experimental Medicine}, publisher={Rockefeller University Press}, author={Judd, Barbi A. and Myung, Peggy S. and Obergfell, Achim and Myers, Erin E. and Cheng, Alec M. and Watson, Stephen P. and Pear, Warren S. and Allman, David and Shattil, Sanford J. and Koretzky, Gary A.}, year={2002}, month=mar, pages={705–717} }